A multifaceted examination of the action of PDE4 inhibitor rolipram on MMP2/9 reveals therapeutic implications

Abstract A PDE4 (phosphodiesterase 4) inhibitor, Rolipram, was previously found to down-regulate (in a manner dependent on cAMP (cyclic adenosine monophosphate)-PKA (protein kinase A)) MMP2 (matrix metalloproteinase 2) and MMP9 protein expression levels, important markers of epithelial-to-mesenchyma...

Full description

Saved in:
Bibliographic Details
Main Authors: Arka Bagchi, Analabha Roy, Anindya Halder, Arunima Biswas
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-95549-y
Tags: Add Tag
No Tags, Be the first to tag this record!